Key terms

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VRTX news

Mar 22 7:16am ET Analyst Issues Sell Rating for Vertex Pharmaceuticals Amid Intensifying Drug Market Competition Mar 21 8:04am ET Vertex Pharmaceuticals announces FDA clearance of VX-407 IND Mar 15 11:15am ET William Blair biotech analysts to hold an analyst/industry conference call Mar 15 4:55am ET William Blair biotech analysts to hold an analyst/industry conference call Mar 14 12:50pm ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call Mar 14 11:41am ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call Mar 13 5:50am ET Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Medtronic (MDT) and Caribou Biosciences (CRBU) Mar 10 5:31pm ET Analysts Are Bullish on These Healthcare Stocks: MacroGenics (MGNX), Irhythm Technologies (IRTC) Mar 06 2:19pm ET William Blair biotech analysts to hold an analyst/industry conference call Mar 06 7:40am ET Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT) Mar 01 9:50am ET Vertex Pharmaceuticals participates in a conference call with JPMorgan Mar 01 5:13am ET Vertex Pharmaceuticals downgraded to Buy from Conviction Buy at Goldman Sachs Mar 01 4:55am ET Vertex Pharmaceuticals participates in a conference call with JPMorgan Feb 29 5:03pm ET Vertex Pharmaceuticals participates in a conference call with JPMorgan Feb 26 8:50pm ET Analysts Offer Insights on Healthcare Companies: Morphic Holding (MORF) and Vertex Pharmaceuticals (VRTX) Feb 23 4:13pm ET Vertex Pharmaceuticals CSO Altshuler sells 3,002 common shares Feb 23 7:20am ET Vertex Pharmaceuticals reports CHMP opinion for label extension of Kalydeco Feb 21 6:26pm ET Crispr Therapeutics price target raised to $112 from $110 at Chardan Feb 21 3:20am ET Analysts Are Bullish on These Healthcare Stocks: Johnson & Johnson (JNJ), Vertex Pharmaceuticals (VRTX) Feb 17 1:02am ET A New Cause for Concern: Vertex Pharmaceuticals Inc. Adds a New Regulation Risk Feb 14 7:34pm ET Vertex Pharmaceuticals initiated with an Outperform at Wolfe Research Feb 14 4:16pm ET Vertex Pharmaceuticals initiated with an Outperform at Wolfe Research Feb 13 5:01pm ET Vertex Pharmaceuticals COO Arbuckle sells over $1.8M in shares Feb 12 9:22am ET Vertex Pharmaceuticals price target raised to $465 from $420 at Argus Feb 08 8:58am ET Crispr Therapeutics price target lowered to $120 from $160 at Truist Feb 08 1:00am ET Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Vertex Pharmaceuticals (VRTX) Feb 07 10:50am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT) Feb 07 8:43am ET Vertex Pharmaceuticals price target lowered to $371 from $378 at Canaccord Feb 07 8:38am ET Recommendation to Sell: Vertex Pharmaceuticals’ Lack of Market Expansion and Competitive Edge Feb 07 8:26am ET Buy Rating Affirmed for Vertex Pharmaceuticals on Strong Clinical and Financial Performance Feb 06 11:15pm ET Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo

No recent press releases are available for VRTX

VRTX Financials

1-year income & revenue

Key terms

VRTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VRTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms